IL6 and diabetic kidney disease: While potential benefits of systemic IL-6 inhibition in DKD patients require further investigation, selective renal targeting of the IL-6 signaling to suppress immune cell invasion and local maturation of Th17 cells and M1 macrophages may open a new therapeutic avenue for improved management of DKD and CKD.